Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Measuring disease activity in SLE is an ongoing struggle

New disease activity measures are needed for systemic lupus erythematosus (SLE). Is the new SLE-DAS better than existing measures or are other instruments, or combined scoring methods, required to manage the spectrum of SLE?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Buyon, J. P. et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142, 953–962 (2005).

    Article  CAS  Google Scholar 

  2. Isenberg, D. A. et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44, 902–906 (2005).

    Article  CAS  Google Scholar 

  3. Thanou, A. et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci. Med. 1, e000005 (2014).

    Article  Google Scholar 

  4. Jesus, D. et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann. Rheum. Dis. (2019).

    Article  PubMed  Google Scholar 

  5. Dolgin, E. Lupus in crisis: as failures pile up, clinicians call for new tools. Nat. Biotechnol. 37, 7–8 (2019).

    Article  Google Scholar 

  6. Merrill, J. T. et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci. Med. 5, e000258 (2018).

    Article  Google Scholar 

  7. Askanase, A. et al. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci. Med. 2, e000075 (2015).

    Article  Google Scholar 

  8. Touma, Z. et al. Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. J. Rheumatol. 38, 275–284 (2011).

    Article  Google Scholar 

  9. Khamashta, M. et al. Sifalimumab, an anti-interferon monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomized, double-blind, placebo controlled study. Ann. Rheum. Dis. 75, 1909–1916 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Anca D. Askanase.

Ethics declarations

Competing interests

The authors declare that they have developed a competing disease activity measure called the LFA-REAL.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Askanase, A.D., Merrill, J.T. Measuring disease activity in SLE is an ongoing struggle. Nat Rev Rheumatol 15, 194–195 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing